内皮微粒与冠心病相关性研究

目的:探讨血浆内皮微粒(EMP)与冠心病的相关性。方法:冠心病组367例,其中稳定型心绞痛(SA)119例,急性冠状动脉综合征(ACS)248例,后者含不稳定型心绞痛(UA)158例,急性心肌梗死(AMI)90例。非冠心病组166例。ELISA法测定血浆ET-1,流式微球技术检测血浆EMP。结果:冠心病组ET-1、EMP水平升高,呈正相关(r=0.233,P=0.001)。ACS组EMP(547.405)显著高于非冠心病组(148.185)及SA组(429.890),亚组分析中UA组EMP(551.660)升高最为显著;冠心病冠状动脉病变支数与EMP无明显相关;AMI患者EMP与BNP、TnT、TnI间无明显相关;EMP与ACS患者短期预后相关(r=0.280,P<0.01)。结论:血浆EMP水平可反映冠心病内皮功能障碍,与冠心病的发生、冠状动脉斑块的不稳定性有关。     

Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease

BACKGROUND: Matrix metalloproteinases (MMP-9 and MMP-2) have been implicated in development of atherosclerosis and plaque rupture in acute coronary syndromes (ACS). AIM: To determine the relationship between circulating MMPs and symptomatic coronary artery disease. METHODS: Plasma levels of MMP-9 and MMP-2 were measured in patients with ACS, stable angina (SA) and in controls, using a quantitative gelatin zymography. These measurements were correlated with markers of systemic inflammation (hs-CRP) in all subjects and myocardial injury (troponin T) in patients with ACS. RESULTS: Plasma MMP-9 in ACS was greater than in SA, and was greater in SA than in controls (P < 0.01 ACS vs SA and controls, P < 0.01 SA vs control). Plasma MMP-2 was significantly greater in ACS than SA or controls (P < 0.01 vs SA and controls). There was strong overall relationship between hs-CRP and MMP-9 (r = 0.65, P < 0.0001) driven by a significant relationship in ACS patients (r = 0.58, P = 0.02), as there was no significant association in SA or controls. A weaker overall correlation was found between hs-CRP and MMP-2 (r = 0.39, P = 0.02), but no significant relationship was present for either of the two patient subgroups or controls. There was no correlation between levels of troponin T and MMP-9, MMP-2 or hs-CRP in ACS patients. CONCLUSION: Quantitative gelatin zymography identifies increased circulating levels of MMP-9 and MMP-2 in patients with symptomatic coronary disease. MMP-9 and MMP-2 are higher in ACS than SA patients and might have use as markers of plaque rupture or instability. The strong relationship between MMP-9 and hs-CRP in ACS patients suggests MMP-9 might be an additional marker and/or consequence of the inflammatory component in ACS.     

斑块稳定性与炎症反应在急性冠状动脉综合征中作用的研究

目的 探讨冠状动脉（冠脉）粥样斑块稳定性和炎症反应在急性冠状动脉综合征（ACS）中的作用。方法 对28例ACS和13例稳定性心绞痛（SA）患者“罪犯”冠脉进行血管内超声（IVUS）检查,同时测定外周血清高敏C反应蛋白（hs-CRP）、基质金属蛋白酶-9（MMP-9）、组织型基质金属蛋白酶抑制剂-1（TIMP-1）、可溶性CD40L（sCD40L）含量。结果 ACS患者冠脉病变处以软斑块为主71．4％（20／28）,SA患者冠脉病变处以硬斑块为主76．9％（10／13）,差异有统计学意义（P=0．004）。与sA组比较,ACS组病变处斑块面积大（P=0．004）、斑块负荷重（P=0．048）、以正性重构为主（P=0．013）。ACS组血清hs—CRP、MMP-9、sCIMOL含量均高于SA组,TIMP-1含量在ACS组和SA组之间差异无统计学意义（P=0．234）,ACS组hs-CRP与MMP-9（r=0．671,P=0．000）、sCIMOL（r=0．494,P=0．008）呈正相关。结论 冠脉“罪犯”病变处结构性易损斑块是ACS发作基础,CIMOL和MMP-9参与的炎症反应导致斑块功能性不稳定和不同临床表现。     

急性冠状动脉综合征患者外周血CD31~(bright)/Annexin V~+内皮微粒水平增高

目的 观察急性冠状动脉综合征患者与非冠心病患者外周血内皮微粒水平,探讨CD31bright/AnnexinV+内皮微粒与心血管危险因素的相关性.方法 急性冠状动脉综合征患者56例,非冠心病患者26例,采用流式细胞仪检测外周血CD31bright/Annexin V+内皮微粒水平.结果 与非冠心病患者比较,急性冠状动脉综合征患者外周血CD31bright/Annexin V+内皮微粒显著增加(P<0.01),而急性心肌梗死与不稳定型心绞痛亚组之间外周血CD31bright/Annexin V+内皮微粒水平无显著性差异(P>0.05).所有入选患者中,2型糖尿病患者外周血CD31bright/Annexin V+内皮微粒水平较非糖尿病患者显著升高(P<0.05);多因素回归分析显示,血清甘油三酯水平与外周血CD31bright/Annexin V+内皮微粒数量独立正相关(r=0.28,P<0.05).急性冠状动脉综合征组血清高敏C反应蛋白水平与外周血CD31bright/Annexin V+内皮微粒数量呈正相关(r=0.31,P<0.05).结论 急性冠状动脉综合征患者和糖尿病患者外周血CD31bright/Annexin V+内皮微粒增多,提示急性冠状动脉综合征患者和2型糖尿病患者内皮损伤严重.CD31bright/Annexin V+内皮微粒水平增高可能与血清甘油三酯和血清高敏C反应蛋白水平增高有关.     

Impact of statin therapy on coronary intervention for non-ST elevation acute coronary syndrome with decreased low-density lipoprotein cholesterol

OBJECTIVES: The benefits of treating patients with acute coronary syndrome (ACS) with statins are well established. This study investigated the effects of statins on patients who presented with low levels of low-density lipoprotein (LDL) cholesterol, were diagnosed with non-ST elevation ACS, and subsequently underwent percutaneous coronary interventions (PCI). METHODS: From 2000 to 2003, 87 patients(mean age 68 +/- 10 years, 69 males, 18 females) underwent PCI because of non-ST elevation ACS, and had low LDL cholesterol on presentation. These patients were divided into two groups: those who had been taking statins (S-group, n = 46), and those not taking statins, or controls (C-group, n = 41). Only patients whose LDL cholesterol was < 100 mg/dl at admission (average: 82 +/- 12 mg/dl) were included in the study. Troponin-T (TnT), creatine kinase (CK), CK-MB, and high-sense C reactive protein (hs-CRP) were measured before and 6 hr after PCI. The two groups were evaluated at 6 months clinical follow-up. RESULTS: There was no difference in these markers before PCI in both groups. TnT and CK-MB in the S-group at 6 hr post-PCI were significantly decreased compared to those of the C-group (0.45 +/- 1.34 vs 1.40 +/- 2.37 ng/ml, respectively, for TnT, p = 0.04; 17.2 +/- 45.5 vs 81.3 +/- 157.2 IU/l, respectively, for CK-MB, p = 0.02). Major adverse cardiac events (MACE) defined as death, myocardial infarction, congestive heart failure and target lesion revascularization were evaluated after 6 months. There was no difference in MACE between the two groups. CONCLUSIONS: Statin treatment before PCI in patients with non-ST elevation ACS demonstrated beneficial effects such as less myocardial damage, even though both groups presented with low LDL cholesterol levels. However, no significant effect on MACE was seen at 6 months after PCI.     

急性冠状动脉综合征急诊介入治疗中用Diver C.E.血栓抽吸器的临床研究

目的评价在急性冠状动脉综合征(ACS)急诊介入治疗中应用Diver C.E.血栓抽吸器的安全性和有效性。方法2005年7月~2006年9月,共70例接受急诊经皮冠状动脉介入治疗(PCI)的ACS患者纳入研究,其中抽吸器组35例,根据冠状动脉造影及临床情况从同期急诊介入治疗的ACS患者中选取35例条件相匹配者作为对照组。比较两组间的基础资料、造影结果和临床预后。结果抽吸器组支架直接置入率高(P=0.009),远端栓塞发生率低(P=0.046),校正的心肌梗死溶栓试验帧数计数值小(P=0.004),心肌灌注分级3级获得率高(P=0.044);急性ST段抬高型心肌梗死中抽吸器组术后肌酸激酶同工酶和肌钙蛋白T峰值浓度较低,ST段回落幅度大,均明显优于对照组(P<0.05),但两组住院期间和中期随访主要心血管事件发生率差异无显著性意义。结论在血栓负荷较重的ACS患者中,急诊PCI时应用Diver C.E.血栓抽吸器安全可行,可显著改善患者术后即刻的远端心肌血流微灌注,减少心肌酶的释放,但远期疗效还需进一步评价。     

Gender-specific and menstrual cycle dependent differences in circulating microparticles

In comparison to age-matched men, young women are at increased risk to suffer from venous thromboembolism (VTE). Some risk factors of inherited and acquired thrombophilia are known, but approximately 30% of the overall risk remains unexplained. Recently, a role for microparticles (MP) in coagulation has been suggested. We investigated, if gender- and menstrual cycle-specific differences in circulating MP exist. Platelet- and endothelial cell-derived microparticles (PMP, EMP) and subpopulations thereof were evaluated flow-cytometrically in healthy women (n = 27) in different phases of their menstrual cycles (follicular phase: n = 14, luteal phase: n = 13) and in healthy men (n = 18). Additionally, D-dimer levels were determined. Compared to men, women had elevated numbers of annexin V-binding MP (p = 0.007), PMP (CD61; p = 0.013), P-selectin-exposing PMP (p = 0.002) and E-selectin-exposing EMP (p = 0.009). During the luteal phase, women had strongly elevated concentrations of MP, PMP, P-selectin- and CD63-exposing PMP as well as E-selectin-exposing EMP (p = 0.001, p < 0.001, p = 0.004, p = 0.003, and p < 0.001, respectively), and the ratio of P-selectin-exposing PMP/platelet increased more than three-fold as compared to men (p = 0.01). When different phases of the menstrual cycle were analysed, MP (annexin V; p = 0.025), PMP (CD61: p < 0.001; CD63: p = 0.015) and E-Selectin-positive EMP (p = 0.006) were all increased in the luteal phase. Although D-dimer concentrations in women were increased compared to men (p = 0 = 0.006), no menstrual cycle-specific differences were observed. In summary, circulating MP and subpopulations thereof are increased in women when compared to men, and this increase seems to be modulated by the menstrual cycle. Therefore, circulating MP may be an additional risk factor contributing to the hitherto unexplained procoagulatory state of young women.     

急性冠脉综合征国产药物支架置入患者血清hs—CRP、sICAM-1和sFas的变化及意义

目的探讨急性冠脉综合征（ACS）国产药物支架置入患者血清高敏C反应蛋白（hs-CRP）、可溶性细胞间黏附分子-1（sICAM-1）和可溶性细胞凋亡因子（sFas）的变化及意义。方法ACS患者55例分为PCI国产药物支架置入35例（观察组）和单纯冠状动脉造影（CAG）检查20例（对照组）,分别测定两组术前、术后1d和术后3d血清hs—CRP、sICAM-1、sFas含量变化。结果观察组术后1d血清hs-CRP、sICAM-1、sFas含量较术前升高（P均〈0．01）,术后3dhs—CRP及sICAM-1较术后1d升高（P均〈0．01）。观察组和对照组血清hs-CRP、sICAM-1、sFas含量在术前无统计学差异（P〉0．05）,而观察组术后1d和术后3d以上三者含量都明显高于对照组（P〈0．01）。血清hs-CRP、sICAM-1和sFas三者之间呈正相关（r=0．272、0．456、0．537,P均〈0．05）。结论国产药物支架置入术可能短时间内触发及加重炎症反应,支架置入患者体内存在动脉内膜平滑肌细胞过度增殖和凋亡不足。     

高负荷剂量氯吡格雷对急性冠脉综合征患者介入治疗后血清sCD40L和hs-CRP浓度的影响

目的探讨高负荷剂量氯吡格雷对急性冠脉综合征(acute coronary syndrome,ACS)患者介入治疗后血清sCD40L和高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)水平的影响。方法选择ACS患者190例分为高负荷剂量组94例(首剂负荷剂量600 mg,以后每天氯吡格雷150 mg,共用7 d,而后以每天氯吡格雷75 mg维持治疗)和标准剂量组96例(首剂负荷剂量300 mg,以后每天氯吡格雷75 mg维持治疗)。于服氯吡格雷前,经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗前,术后第1天,术后第7天,术后第30天血清sCD40L和hs-CRP的浓度,并记录患者术后1、3、6个月发生主要心血管事件、出血事件的情况。结果高负荷剂量组PCI治疗后不同时间点血清可溶性CD40配体(sCD40L)、hs-CRP浓度均低于标准剂量组,差异有统计学意义(P<0.05)。sCD40L与hs-CRP的变化趋势的相关性检验结果显示两者呈正相关(皮尔森相关系数r=0.128,P<0.001)。结论高剂量氯吡格雷比标准剂量氯吡格雷对sCD40L、hs-CRP的抑制作用更强;当氯吡格雷抑制炎症反应产物hs-CRP产生的同时也会抑制炎症产物sCD40L的产生。     

芪参益气滴丸对急性冠脉综合征患者冠状动脉介入治疗术后炎症趋化因子水平的影响

目的:观察芪参益气滴丸对急性冠脉综合征(ACS)患者冠状动脉介入治疗(PCI)术后血清炎症趋化因子高敏C反应蛋白(hs-CRP)、1型纤溶酶激活物抑制剂(PAI-1)、内皮素-1(ET-1)水平的影响.方法:选择100例行PCI的ACS患者,随机分为芪参益气滴丸口服+常规治疗(芪参组,n=50)与常规治疗(对照组,n=50),比较两组PCI术前1 d、PCI术后24 h、PCI术后第4周血清高敏C反应蛋白、1型纤溶酶激活物抑制剂、内皮素-1的差异.结果:共有100例完成试验,其中男性70例,女性30例,与对照组比较,PCI术前1 d、PCI术后24 h,芪参组的血清高敏C反应蛋白、1型纤溶酶激活物抑制剂、内皮素-1水平差异无统计学意义(P均＞0.05);芪参组PCI术后4周的高敏C反应蛋白、1型纤溶酶激活物抑制剂和内皮素-1有明显回落(P＜0.05～0.01),差异均有统计学意义;本组间与PCI术前1 d比较,PCI术后24 h及PCI术后4周的血清高敏C反应蛋白、1型纤溶酶激活物抑制剂、内皮素-1浓度均较术前1 d有明显改变(PCI术后24 h为增加,PCI术后4周为回落,P均＜0.01),差异均有统计学意义.结论:芪参益气滴丸可降低ACS患者PCI术后血清炎症趋化因子的水平.     

High levels of circulating endothelial microparticles in patients with acute coronary syndromes

Background

Endothelial injury plays a critical role in coronary artery disease (CAD), but the assessment of this injury has been problematical. Recently, it has been shown in vitro that endothelial cells (ECs) release endothelial microparticles (EMPs) on activation or apoptosis and that an assay of EMPs can provide useful information on EC status in patients with thrombotic disorders. This study is aimed at assessing possible correlations between EMPs, which are markers of endothelial injury, and clinical subgroups of patients with CAD.

Methods

A prospective, case-controlled study was conducted on 84 patients with CAD and 42 control subjects to investigate EMP profiles. Included were 64 patients with acute coronary syndromes ([ACS], 38 with myocardial infarction [MI] and 26 with unstable angina [UA]) and 20 patients with stable angina (SA). EMPs in platelet-poor plasma were measured flow cytometrically with combinations of fluorescent antibodies (anti-CD31, -51, -42), allowing distinction of EMPs from platelet microparticles (PMPs). Clinical subgroups of patients were correlated with EMP and PMP levels in blood.

Results

Two species of EMPs (CD31+ and CD51+) were evaluated. Both were significantly higher in patients with CAD than in control subjects. CD31+ EMP was higher in ACS than SA. Among patients with first MI, CD31+ EMP was higher in patients with MI than in patients with UA and was significantly higher than in patients with recurring MI. CD51+ EMP did not discriminate ACS from SA. A simultaneous assay of PMP showed correlation between EMPs and PMPs. However, PMPs did not discriminate patients with SA from control subjects.

Conclusions

EMP assay appears promising for assessing EC injury in CAD.     

急性冠状动脉综合征患者载脂蛋白A5检测及其意义

目的 探讨血清载脂蛋白A5(APOA5)水平与急性冠状动脉综合征(ACS)患者血脂谱及高敏性C反应蛋白(hs-CRP)的关系.方法 入选587例受试对象,分为对照组(n=232)、稳定性心绞痛(SA)组(n=127)、不稳定性心绞痛(UA)组(n=116)和急性心肌梗死(AMI)组(n=112).抽血分离血清,分别采用ELISA法和免疫比浊法测定血清APOA5以及hs-CRP,并测定血清甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C).比较各组ApoA5、hs-CRP和血脂的血清浓度差异,分析三者之间的相互关系.结果 UA组[(340.6±63.5)μg/L]和AMI组[(373.2±73.8)μg/L]的ApoA5浓度明显高于对照组[(108.7±23.2)μg/L]和SA组[(78.3±20.2)μg/L](均P<0.05).UA组和AMI组的ApoA5与TG(r=0.63和0.67,P<0.05)和hs-CRP(r=0.57和0.55,P<0.05)呈正相关,而ApoA5与TC、HDL-c和LDL-C无明显相关(P>0.05).结论 ACS患者中血清ApoA5浓度显著升高,与血清TG或hs-CRP浓度显著正相关,提示ApoA5的代谢和生理功能在ACS期间均发生了变化,这可能与炎症反应增强有关.     

联合检测肌钙蛋白T、高敏C反应蛋白和B型钠尿肽对非ST段抬高的急性冠状动脉综合征预后诊断的价值

目的探讨联合检测肌钙蛋白T、高敏C反应蛋白、B型钠尿肽对非ST段抬高的急性冠状动脉综合征预后诊断的价值。方法检测145例经冠状动脉造影证实的非ST段抬高的急性冠状动脉综合征患者肌钙蛋白T、高敏C反应蛋白、B型钠尿肽的水平。随访急性冠状动脉综合征患者12个月，观察终点为心肌梗死新发或再发和心源性死亡。结果多因素logistic回归分析发现肌钙蛋白T、高敏C反应蛋白、B型钠尿肽可独立预测非ST段抬高急性冠状动脉综合征患者远期预后。经过已知的临床危险因素校正后，心脏生化标志物异常的数目仍然是其心血管事件重要危险因子。结论联合检测肌钙蛋白T、高敏C反应蛋白、B型钠尿肽对急性冠状动脉综合征患者长期预后有重要的临床价值。     

Relationship between interleukin-18 levels and characterization of atherosclerotic plaque and percutaneous coronary intervention

Background lnterleuldn-18(IL- 18) plays a key role in the development,progression and outcome of coronary artery disease and its complications.However,its variability relation to the characterization of atherosclerotic plaque and percutaneous coronary intervention are still unknown.Methods Fifty four patients with coronary artery disease [22 patients with stable angina (SA) and 32 patients with acute coronary syndrome (ACS)] were enrolled in this study.All patients underwent percutaneous coronary intervention (PCI).The stability of the plaques at the criminal vessels was assessed with analogical IVUS.Serum IL-18 levels were measured at the time points of 5 rain before PCI,and Oh,6h,24h and lmonth after PCI in all patients.Results ACS group consisted mainly of lipidic unstable plaques while SA group of fibrous stable plaques.Moreover,compared with those in SA group,eccentricity index (EI) and remodeling index (RI) were significantly higher in ACS group.Positive remodeling was seen in ACS group while negative or no remodeling in SA group.Further,serum IL-18 levels were significantly elevated in patients with ACS than those in SA group before PCI,increased at Oh,6h,24h after PCI (P＜0.05)and were not significant different at 1 month after PCI from those before PCI.Conclusions There is significant difference in the composition and structural characteristics of atherosclerotic plaques between ACS and UA groups.PCI triggersd and enhances the inflammatory response in a short time.Serum levels of IL- 18 are the predictors of progression of unstable plaque in atherosclerosis.Post-operative complications of PCI might be reduced by inhibiting IL- 18.(J Geriatr Cardiol 2008;5:21-24)     

氟伐他汀早期干预对急性冠状动脉综合征患者血清炎症因子水平的影响

目的探讨不同剂量氟伐他汀早期干预治疗对急性冠状动脉综合征(ACS)患者血清高敏C反应蛋白(hsCRP)、TNFα水平的影响。方法58例ACS患者随机分为A组常规治疗;B组为常规治疗加氟伐他汀40mg/d;C组为常规治疗加氟伐他汀80mg/d;稳定性冠心病患者为对照组。ACS患者在治疗1周前后分别测定血清hsCRP、TNFα及血脂水平。结果(1)ACS患者的血清hsCRP、TNFα水平明显高于稳定性冠心病患者(P<005)。(2)40mg/d和80mg/d氟伐他汀治疗1周后血清hsCRP及TNFα水平均有明显下降(P值均<001),而以80mg/d氟伐他汀组作用更明显。(3)Pearson相关分析显示ACS患者血清hsCRP与TNFα水平呈正相关(r=070,P<001),hsCRP和TNFα与血脂水平不相关。结论ACS患者血清炎症因子水平增高,早期氟伐他汀治疗可降低ACS患者的血清hsCRP和TNFα水平,且呈剂量依赖性。氟伐他汀的抗炎作用独立于降脂作用之外。早期他汀类药物强化治疗可能使ACS患者获益更大。     

三种微颗粒水平在糖尿病血管病变中的意义

目的 分析糖尿病患者微颗粒(包括血小板微颗粒、内皮细胞微颗粒以及组织因子阳性微颗粒)水平,探讨微颗粒水平与糖尿病并发症的相关性.方法 流式细胞仪检测106例糖尿病患者和50例健康志愿者血浆中血小板微颗粒、内皮细胞微颗粒和组织因子阳性微颗粒水平,并比较糖尿病血管病变各组间微颗粒的变化.结果 糖尿病组血小板微颗粒和组织因子阳性微颗粒水平与对照组比较无明显差异(23.09±15.66对38.55±28.56,83.82±82.61对89.06±82.75,均P>0.05),而内皮细胞微颗粒水平在糖尿病组明显高于对照组(164.20±128.88对63.81±40.84,P<0.05),合并有血管病变者其内皮细胞微颗粒水平又高于单纯糖尿病组(184.12±152.77、188.21±149.55对138.53±99.87,P<0.05).结论 内皮细胞功能异常是糖尿病患者,尤其合并有血管病变患者内皮细胞微颗粒升高的原因;内皮细胞微颗粒水平可以用来评价糖尿病患者血管内皮细胞的功能状态和疾病的进展的指标之一.     

芪参益气滴丸对冠状动脉介入术后炎症因子及心脏不良事件的影响

目的 观察芪参益气滴丸对急性冠脉综合征（ACS）患者经皮冠状动脉介入术（PCI）后炎症因子及主要不良心脏事件（MACE,包括复发心绞痛、急性心肌梗死、严重心律失常、心力衰竭、冠心病死亡）影响.方法纳入60例行PCI的ACS患者,随机分为常规治疗组（n=30）和芪参益气滴丸联合常规治疗组（芪参组,n=30）,采用酶联反应吸附法（ELISA法）比较两组术后24h和术后6个月血清高敏C反应蛋白（hs-CRP）、可溶性CD40配体（sCD40L）及基质金属蛋白酶-9（MMP-9）水平变化,并比较两组6个月MACE事件发生率.结果术后24h两组血清hs-CRP、sCD40L和MMP-9水平均无统计学差异（P＞0.05）;6个月后,两组hs-CRP、sCD40L和MMP-9水平分别是3.18±0.71mg/l、5.86±2.01 ng/dl和240.56±60.6 ng/dl.与对照组相比,芪参组血清hs-CRP、sCD40L及MMP-9均明显降低,差异有统计学意义（P＜0.05）,随访6个月,芪参组MACE发生率较对照组更低（13.33% vs.26.67%,P＜0.05）,且差异有统计学意义.结论 芪参益气滴丸可降低介入术后炎症因子hs-CRP、SCD40L和MMP-9的水平,同时降低MACE近期发生率.     

高敏C-反应蛋白与白介素-6在急性冠状动脉综合征意义

目的 探讨急性冠状动脉综合征(acute coronary symptom,ACS)病人血清高敏C反应蛋白(high sensitivity-C reactive protein,hs-CRP)和白介素-6(interleukin-6,IL-6)浓度的变化及临床意义.方法 ACS组ACS病人60例,稳定型心绞痛(stable angina pectoris,SAP)组病人40例,对照组为40名健康人,检测血清IL-6、hs-CRP水平.结果 ACS组血清IL-6、hs-CRP水平明显高于SAP组和对照组(P＜0.01);ACS组中,急性心肌梗死病人又高于不稳定型心绞痛病人(P＜0.05);SAP组与对照组差异无统计学意义(P＜0.05);血清IL-6和hs-CRP水平呈正相关(r=0.5942,P＜0.01).结论 ACS病人血清IL-6和hs-CRP升高,其水平变化反映ACS的严重程度.     

急性冠脉综合征行急诊PCI术后hs-CRP和NT-proBNP的临床意义及其预测价值

目的:观察高敏C反应蛋白(hs-CRP)和氨基末端脑钠尿肽原(NT-proBNP)在急性冠脉综合征(ACS)行急诊冠状动脉介入治疗(PCI)术前后的临床意义及其近期预后的预测价值。方法:选择从2009年2月~2011年4月入住两家医院的ACS患者101例,均已成功行急诊PCI术,术后24 h、72 h~7 d、3~6个月测定血清hs-CRP和NT-proBNP水平;并观察随访3~6个月的主要心脏不良事件(MACE)。同时观察ACS药物治疗组52例,健康对照组40例,并进行对比分析。结果:药物治疗组的近期血清NT-proBNP水平显著高于PCI组;而药物治疗组的72 h~7d的血清hs-CRP水平显著高于PCI组;近期PCI组的MACE事件低于药物治疗组。结论:急诊PCI组3~6个月内治疗效果优于药物治疗组。血清NT-proBNP能够对ACS患者进行危险分层,预测MACE的发生率;hs-CRP可作为行急诊PCI的ACS患者的近期预后的预测因子。     

急性冠脉综合征患者血清同型半胱氨酸和hs-CRP的相关性

目的:探讨急性冠脉综合征(ACS)患者血清同型半胱氨酸水平的变化,评价其与高敏C反应蛋白(hs-CRP)的关系。方法:用免疫比浊透视法测定60例ACS患者和30例对照组血清中hs-CRP水平,以循环酶法测定血清同型半胱氨酸(Hcy)水平。结果:ACS组Hcy水平[(16.75±6.40)mg/L]明显高于对照组[(13.70±6.60)mg/L],P<0.05,AMI组的hs-CRP和Hcy水平明显高于UAP组(P<0.05),且ACS组血清Hcy水平升高[(16.75±6.40)mg/L]时,患者血清hs-CRP水平[(4.475±16.09)mg/L]也相应升高,两者之间呈正相关(r=0.444,P<0.01)。结论:血清同型半胱氨酸水平升高与心肌损伤程度有关,且可能通过hs-CRP加重心肌损伤。